Chemomab Therapeutics
CMMB
10 hedge funds and large institutions have $1.03M invested in Chemomab Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 5 closing their positions.
1.94% more ownership
Funds ownership: 5.61% → 7.54% (+1.9%)
29% less funds holding
Funds holding: 14 → 10 (-4)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
79% less capital invested
Capital invested by funds: $4.91M → $1.03M (-$3.88M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$111K |
| 2 |
Jane Street
New York
|
+$60.4K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$8.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.16M |
| 2 |
O
OrbiMed
New York
|
-$1.09M |
| 3 |
YLHM
Yelin Lapidot Holdings Management
Tel Aviv,
Israel
|
-$671K |
| 4 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
-$36.2K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$30.4K |
CMMB Hedge Fund Activity: Q3 2025 in Review
10 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q3 2025, worth a combined $1.03M — down 79% from $4.91M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CMMB and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $111K. The largest seller was Morgan Stanley, cutting an estimated $1.16M.
- 10 institutional investors held Chemomab Therapeutics (CMMB) as of Q3 2025, down from 14 in Q2 2025.
- Funds reported $1.03M of Chemomab Therapeutics stock for Q3 2025, down 79% quarter-over-quarter.
- 1 fund opened new Chemomab Therapeutics positions in Q3 2025 and 5 closed out, a net change of -4 holders.
- The largest Chemomab Therapeutics buyer in Q3 2025 was Stonepine Capital Management, an estimated $111K added.
- The largest Chemomab Therapeutics seller in Q3 2025 was Morgan Stanley, an estimated $1.16M sold.
Based on aggregated 13F filings for Q3 2025.